IVIG Market Analysis: Rising Demand to Drive USD 21.06 Billion Valuation by 2030

The global Intravenous Immunoglobulin Market was valued at USD 11.17 billion in 2021 and is projected to grow from USD XX billion in 2022 to USD 21.06 billion by 2030, at a CAGR of 7.3% during the forecast period (2022–2030).

Market Catalysts for Expansion

The growth of the Intravenous Immunoglobulin (IVIG) Market is driven by the rising prevalence of immunodeficiency disorders, increased awareness of IVIG therapy, and technological advancements in plasma-derived products. The growing geriatric population, which is more susceptible to immune system disorders, along with an increasing number of FDA approvals for IVIG therapies, further fuels market expansion. Additionally, the demand for immunoglobulin treatments for neurological diseases is contributing to market growth.

Market Segment Breakdown

By Application:

• Hypogammaglobulinemia

• Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

• Immunodeficiency Diseases

• Congenital AIDS

• Chronic Lymphocytic Leukemia

• Myasthenia Gravis

• Multifocal Motor Neuropathy

• Immune Thrombocytopenic Purpura (ITP)

• Kawasaki Disease

• Guillain-Barré Syndrome

By Distribution Channel:

• Hospital Pharmacy

• Specialty Pharmacy

Top Performing Companies

• Baxalta Incorporated

• Biotest AG

• China Biologic Products Inc.

• CSL Behring LLC

• Grifols S.A.

• Kedrion S.p.A.

• LFB Biomedicaments S.A.

• Octapharma AG

• Sanquin Plasma Products B.V.

• Bharat Serums and Vaccines Limited

Download Free Sample Report with Complimentary Analyst Consultation : https://straitsresearch.com/report/intravenous-immunoglobulin-market/request-sample

Emerging Prospects

The market is expected to witness further growth with ongoing research into novel immunoglobulin therapies and increasing government initiatives to support plasma collection and immunoglobulin production. Advances in recombinant immunoglobulins and subcutaneous alternatives also provide promising opportunities.

Industry Movements

Several key industry movements are shaping the IVIG Market, including strategic acquisitions, collaborations, and expansion initiatives by major players. Increased investment in R&D, particularly for treating neurological and autoimmune disorders, is enhancing the therapeutic landscape. Regulatory advancements are also facilitating quicker approval of IVIG products.

Geographic Analysis

North America holds the largest market share due to well-established healthcare infrastructure and strong government support for immunoglobulin therapies. Europe follows closely with increasing awareness and adoption of plasma-derived products. The Asia-Pacific region is expected to witness the highest growth rate due to a rising prevalence of immunodeficiency diseases and expanding healthcare expenditure in countries such as China, India, and Japan.

Data Insights

The market's steady growth is supported by an increase in plasma collection centers, technological innovations, and improvements in cold chain logistics for the safe transportation of IVIG products. With the growing demand for personalized medicine, new formulations of IVIG therapy are likely to gain traction in the coming years.

Contact Us

Email: sales@straitsresearch.com
Address: 825 3rd Avenue, New York, NY, USA, 10022
Phone: +1 646 905 0080 (US), +91 8087085354 (India), +44 203 695 0070 (UK)